Roche to discontinue production of nelfinavir and saquinavir 200 mg hard capsules
1 October 2012. Related: Antiretrovirals.
2012
Volume 13 Number 7/8 July/August 2012
1 August 2012. Related: Editorial.
HIV and your quality of life: a guide to side effects and other complications (July 2012)
1 August 2012. Related: Supplements.
i-Base/TAG 2012 pipeline report
1 August 2012. Related: Supplements.
19th IAS World AIDS Conference, 22–25 July 2012, Washington
1 August 2012. Related: Conference reports.
IAS: social and political talks online as web casts
1 August 2012. Related: Conference reports, Treatment access, Treatment advocacy.
New booster – cobicistat as an alternative to ritonavir
1 August 2012. Related: Conference reports, Antiretrovirals.
Dolutegravir vs raltegravir in treatment-naive patients: 48 week results from the SPRING 2 study
1 August 2012. Related: Conference reports, Antiretrovirals.
Elvitegravir vs raltegravir: 96 week phase III results in treatment experienced patients
1 August 2012. Related: Conference reports, Antiretrovirals.
In vitro and animal data support safety profile BMS 986001: d4T-like NRTI currently in clinical trials
1 August 2012. Related: Conference reports, Antiretrovirals.
Switching to rilpivirine/tenofovir/FTC fixed dose combination from boosted-PI regimen: SPIRIT study draws the line at 24 weeks
1 August 2012. Related: Conference reports, Antiretrovirals.
Maraviroc plus atazanavir/ritonavir in a nuke-sparing regimen in treatment-naive patients
1 August 2012. Related: Conference reports, Antiretrovirals.
Five-year results from raltegravir registrational studies
1 August 2012. Related: Conference reports, Antiretrovirals.
First report: atazanavir-related gallstones (cholelithiasis)
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Paediatrics studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics
1 August 2012. Related: Conference reports, Paediatric care.
Novel lopinavir/ritonavir sprinkle formulation for children in resource-limited settings
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Update on new antiretrovirals for children and adolescents
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Tenofovir prophylaxis for neonates
1 August 2012. Related: Conference reports, Pregnancy, Paediatric care.
Efavirenz levels variable in children in the CHAPAS-3 study
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
Early initiation of ART is associated with growth recovery in children in NEVEREST-2
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
High prevalence of peripheral neuropathy in children taking d4T in rural South Africa
1 August 2012. Related: Conference reports, Paediatric care, Side effects.
Lipid profile in children in PREDICT: immediate versus deferred nevirapine-based ART
1 August 2012. Related: Conference reports, Antiretrovirals, Paediatric care.
High levels of maraviroc in rectal tissue fail to protect macaques from SIV transmission following rectal exposure
1 August 2012. Related: Conference reports, HIV prevention and transmission.
Mechanisms for circumcision to reduce HIV transmission in different penile tissue: target cell differences rather than keratinisation
1 August 2012. Related: Conference reports, HIV prevention and transmission.
Towards an HIV cure: early developments reported
1 August 2012. Related: Conference reports, Cure-related research, Basic science and immunology.
Important publications launched at IAS 2012
1 August 2012. Related: Conference reports, Other news.
14th International Workshop on Co-morbidities and Adverse Drug Reactions (IWCADR), 19–21 July 2012, Washington
1 August 2012. Related: Conference reports.
Skeletal muscle toxicity and raltegravir
1 August 2012. Related: Conference reports, Antiretrovirals, Side effects.
Proteinuria as a potential early marker of tenofovir-related renal toxicity
1 August 2012. Related: Conference reports, Side effects.
Earlier and greater comorbidities reported in HIV positive cohort
1 August 2012. Related: Conference reports, Side effects.
20th International HIV Drug Resistance Workshop, 9–13 June 2012, Sitges
1 August 2012. Related: Conference reports.
In vitro resistance profile for BMS 986001
1 August 2012. Related: Conference reports, Drug resistance.
Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B
1 August 2012. Related: Conference reports, Drug resistance.
Defective viral reservoir populations is common in patients on long-term suppressed ART
1 August 2012. Related: Conference reports, Drug resistance.
First case report of transmission with five-class resistance
1 August 2012. Related: Conference reports, Drug resistance.
New data on the Berlin patient: interpret with caution
1 August 2012. Related: Conference reports, Basic science and immunology, Drug resistance.
Dolutegravir indicates superiority compared to efavirenz in treatment-naïve patients: top-line results only
1 August 2012. Related: Antiretrovirals.
FDA update to darunavir label: severe skin reactions
1 August 2012. Related: Antiretrovirals.
FDA approval of generic ARVs
1 August 2012. Related: Treatment access.
Activists protest at IAS for Global Fund to stick to principles
1 August 2012. Related: Treatment access.
EU parliament rejects anti-counterfeiting trade agreement: allows continued access to generic medicines
1 August 2012. Related: Treatment access.
US trade deal threatens access to medicines
1 August 2012. Related: Treatment access.
Theratechnologies withdraw EU application for tesamorelin (Egrifta)
1 August 2012. Related: Side effects.
FDA approve Truvada to reduce the risk of sexual transmission
1 August 2012. Related: HIV prevention and transmission.
Recent studies on HIV, ART and osteoporotic fracture risk
1 August 2012. Related: Side effects.
Role of cell-to-cell transmission in sustaining the HIV reservoir
1 August 2012. Related: Basic science and immunology.
ACT-UP in film: ‘How to survive a plague’ and ‘United in anger’
1 August 2012. Related: Book and film reviews.
PLoS Medicine (July 2012)
1 August 2012. Related: On the web.
AIDS 2012: non-technical conference summaries: HTB supplement
1 August 2012. Related: Special reports.
Volume 13 Number 7/8 July/August 2012 PDF
1 August 2012. Related: PDFs.
2012 pipeline report launched in Washington: HIV, HCV, TB, PEP, cure and vaccine research
21 July 2012. Related: Editorial.
Press release: 2012 pipeline report launched in Washington
21 July 2012. Related: Editorial.
HTB supplement: 2012 pipeline report
21 July 2012. Related: Editorial, Special reports.
Introduction and executive summary
21 July 2012. Related: Pipeline report.
The antiretroviral pipeline 2012
21 July 2012. Related: Pipeline report.
The pediatric antiretroviral pipeline
21 July 2012. Related: Pipeline report.
Retrofitting for purpose: treatment optimisation 2012
21 July 2012. Related: Pipeline report, Fit for purpose.
Preventive technologies, research toward a cure, and immune-based and gene therapies
21 July 2012. Related: Pipeline report, Cure-related research.
Hepatitis C drug development goes from pony ride to rocket launch
21 July 2012. Related: Pipeline report.
Hepatitis C (HCV) treatment access: spotlight on Thailand/Asia
21 July 2012. Related: Pipeline report.
The tuberculosis diagnostics pipeline
21 July 2012. Related: Pipeline report.
The tuberculosis treatment pipeline
21 July 2012. Related: Pipeline report.
The tuberculosis vaccine pipeline
21 July 2012. Related: Pipeline report.
Acknowledgments
21 July 2012. Related: Pipeline report.
Volume 13 Number 5/6 May/June 2012
1 June 2012. Related: Editorial.